Articles: function.
-
The Effect of Serum Vitamin D Level in Korean Chronic Obstructive Pulmonary Disease (COPD) Patients.
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To determine the relationship of serum vitamin D level with lung function, acute exacerbation, 6 minute walking (6MW) distance, and quality of life. ⋯ The following authors have nothing to disclose: Ji Ye Jung, Ah Young Leem, Eu Dong Hwang, Song Yee Kim, Se Kyu Kim, Joon ChangNo Product/Research Disclosure Information.
-
Physiology/PFTs/Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Compare symptons, respiratory function evolution and survival of patients with bulbar presentation amyothrophic lateral sclerosis and spinal presentation amyothrophic lateral sclerosis. ⋯ The following authors have nothing to disclose: Artur Vale, Ana Ferreira, Elsa Matos, Duarte Rocha, Bebiana CondeNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To compare the long-term effect of riociguat in PAH patients in FC I/II versus FC III/IV at PATENT-1 baseline. ⋯ Gisela Meyer: Consultant fee, speaker bureau, advisory committee, etc.: Gisela Meyer has received advisory board and speaker fees from Bayer, Lilly and GlaxoSmithKline. Nazzareno Galiè: Grant monies (from industry related sources): Nazzareno Galiè received grant money paid to his institution by Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Nazzareno Galiè received consulting fees, honorariums and/or support for travel to meetings from Bayer. Friedrich Grimminger: Grant monies (from industry related sources): Friedrich Grimminger has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Friedrich Grimminger has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare. Ekkehard Grünig: Consultant fee, speaker bureau, advisory committee, etc.: Ekkehard Grünig received support for travel to meetings from Bayer Pharma. Marc Humbert: Consultant fee, speaker bureau, advisory committee, etc.: Marc Humbert has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Zhi-Cheng Jing: Consultant fee, speaker bureau, advisory committee, etc.: Zhi-Cheng Jing has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Anne M. Keogh: Grant monies (from industry related sources): Anne M. Keogh has received grant money paid to her institution from Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Anne M. Keogh has received consultancy fees from Bayer. David Langleben: Grant monies (from industry related sources): David Langleben received grant money paid to his institution from Bayer Inc., Consultant fee, speaker bureau, advisory committee, etc.: David Langleben received consulting fees/honorarium, paid to his institution by Bayer Inc., Other: David Langleben received fees for participation in review activities, paid to his institution by Bayer Inc. Lewis J Rubin: Consultant fee, speaker bureau, advisory committee, etc.: Lewis J. Rubin has received consulting fees, honorarium and/or support for travel to meetings from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia., Other: Lewis J. Rubin has received fees for participation in review activities from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia. Arno Fritsch: Shareholder: Arno Fritsch has received stock/stock options from Bayer HealthCare., Employee: Arno Fritsch is a full-time employee of Bayer HealthCare. Neil Davie: Employee: Neil Davie is a full-time employee of Bayer HealthCare. Hossein-Ardeschir Ghofrani: Grant monies (from industry related sources): Hossein-Ardeschir Ghofrani has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Hossein-Ardeschir Ghofrani has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare.Riociguat is an investigational new drug currently in process for registration submission to health authorities, after successful finalisation of a RCT in patients with PAH.
-
Thoracic Surgery PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To delineate a successful approach to treating synchronous primary lung cancers arising simultaneously with one primary in each lung. The primary which appears to be more advanced clinically is resected first. The second is resected as soon as possible after the patient has rcovered adequately from the first procedure. ⋯ The following authors have nothing to disclose: Geoffrey Graeber, Syed Quadri, Karl UyNo Product/Research Disclosure Information.
-
ILD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pulmonary complications of connective tissue disease (CTD) are common. Recent studies have shown benefit with rituximab (RTX) in the treatment of CTD related interstitial lung disease1,2. We performed a review to assess the benefit of RTX in five patients with pulmonary complications of CTD. ⋯ The following authors have nothing to disclose: Deirdre Fitzgerald, Sinead Harney, Michael HenryNo Product/Research Disclosure Information.